- Home
- HLP vs LCTX Comparison
HLP vs LCTX Comparison
Compare HLP & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- LCTX
- Stock Information
- Founded
- HLP 2021
- LCTX 1990
- Country
- HLP China
- LCTX United States
- Employees
- HLP N/A
- LCTX N/A
- Industry
- HLP Industrial Machinery/Components
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLP Industrials
- LCTX Health Care
- Exchange
- HLP Nasdaq
- LCTX Nasdaq
- Market Cap
- HLP 107.3M
- LCTX 127.7M
- IPO Year
- HLP 2023
- LCTX N/A
- Fundamental
- Price
- HLP $1.30
- LCTX $0.59
- Analyst Decision
- HLP
- LCTX Strong Buy
- Analyst Count
- HLP 0
- LCTX 5
- Target Price
- HLP N/A
- LCTX $4.80
- AVG Volume (30 Days)
- HLP 43.0K
- LCTX 2.4M
- Earning Date
- HLP 12-19-2024
- LCTX 03-06-2025
- Dividend Yield
- HLP N/A
- LCTX N/A
- EPS Growth
- HLP N/A
- LCTX N/A
- EPS
- HLP N/A
- LCTX N/A
- Revenue
- HLP $14,045,084.00
- LCTX $8,719,000.00
- Revenue This Year
- HLP N/A
- LCTX N/A
- Revenue Next Year
- HLP N/A
- LCTX $41.15
- P/E Ratio
- HLP N/A
- LCTX N/A
- Revenue Growth
- HLP N/A
- LCTX N/A
- 52 Week Low
- HLP $0.99
- LCTX $0.48
- 52 Week High
- HLP $3.44
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- HLP 47.31
- LCTX 51.92
- Support Level
- HLP $1.25
- LCTX $0.54
- Resistance Level
- HLP $1.47
- LCTX $0.60
- Average True Range (ATR)
- HLP 0.09
- LCTX 0.04
- MACD
- HLP -0.00
- LCTX 0.01
- Stochastic Oscillator
- HLP 22.73
- LCTX 82.62
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.